Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Waters

Showing results (111-120 of 134) with videos related to

Pageof 14
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 14, 2021
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical TrialsKristine M Erlandson, Christoph C Carter, Kathleen Melbourne, et al.
HIV Medicine|December 12, 2022
BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022Laura Waters, Alan Winston, Iain Reeves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 TrialMarcelo V Negrao, Alvaro G Paula, David Molkentine, et al.
HIV Medicine|December 17, 2020
British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020Adrian Palfreeman, Ann Sullivan, Michael Rayment, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.
PLOS Global Public Health|February 14, 2025
International healthcare workers' experiences and perceptions of the 2022 multi-country mpox outbreakVanessa Apea, Boghuma K Titanji, Francesca H Dakin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2018
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.
Nature|March 6, 2019
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantationRavindra K Gupta, Sultan Abdul-Jawad, Laura E McCoy, et al.
Pageof 14

Showing results (111-120 of 134) with videos related to

Sort By:
Pageof 14
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 14, 2021
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical TrialsKristine M Erlandson, Christoph C Carter, Kathleen Melbourne, et al.
HIV Medicine|December 12, 2022
BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022Laura Waters, Alan Winston, Iain Reeves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 TrialMarcelo V Negrao, Alvaro G Paula, David Molkentine, et al.
HIV Medicine|December 17, 2020
British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020Adrian Palfreeman, Ann Sullivan, Michael Rayment, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.
PLOS Global Public Health|February 14, 2025
International healthcare workers' experiences and perceptions of the 2022 multi-country mpox outbreakVanessa Apea, Boghuma K Titanji, Francesca H Dakin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2018
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.
Nature|March 6, 2019
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantationRavindra K Gupta, Sultan Abdul-Jawad, Laura E McCoy, et al.
Pageof 14